Icosapent Ethyl (Vascepa): Research, Dosing, and Where to Buy in 2026
A research-first profile for Icosapent Ethyl (Vascepa) (Vescapa, Vascepa, EPA ethyl ester), aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
Icosapent Ethyl (Vascepa) is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 12 PubMed-cited papers, 1 attributed expert mention, and 1 transcript dosing protocol for Icosapent Ethyl (Vascepa), each linked to its source.
- Also indexed as Vescapa, Vascepa, EPA ethyl ester.
- 1 aggregated dosing-protocol mention from source transcripts.
- 12 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
- Evidence level in this entry is marked as fda_approved.
What is Icosapent Ethyl (Vascepa)?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
Experts on background and overview · 1 cited mention
"The EPA RX fish oil of Vascepa and Icosapent have shown clear cardiac benefits."
What is Icosapent Ethyl (Vascepa) researched for?
Prescription purified EPA fish oil for lowering triglycerides and CV risk.
Icosapent Ethyl (Vascepa) Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
| Speaker | Source | Timestamp | Protocol | Evidence |
|---|---|---|---|---|
| Leo and Longevity (Lucie) | How to Improve Cognitive Brain Function from a Neuroscientist | 00:22:35 | The host reported using 2 g EPA in the morning on empty stomach | anecdotal |
Where to Buy Icosapent Ethyl (Vascepa) in 2026
No tracked vendor recommendations for Icosapent Ethyl (Vascepa) yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
What Experts Say
1 expert across our source library discuss Icosapent Ethyl (Vascepa). Each entry is that expert’s most context-rich mention: click to watch it at the exact timestamp in the original video. Quotes are also emitted as Schema.org Quotation JSON-LD for AI assistants.
-
“The EPA RX fish oil of Vascepa and Icosapent have shown clear cardiac benefits.”
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about Icosapent Ethyl (Vascepa). Each line links to the original source.
- "**RESULTS**: The median age was 69 years (interquartile range [IQR], 59-77 years), and 60.6% of the participants were male." · Yanagisawa N et al, 2026 PubMed
- "AF was diagnosed in 908 (9.9%) patients." · Yanagisawa N et al, 2026 PubMed
- "Fewer than 30% of patients reach LDL-c targets with statins alone." · Han J et al, 2026 PubMed
- "Six trials (n = 42,738; 31-85% male) were eligible." · Faheem MA et al, 2026 PubMed
- "**RESULTS**: EPA-based therapy significantly reduced hospitalizations for unstable angina (RR 0.75, 95% CI 0.66-0.87; I2 = 0%)." · Faheem MA et al, 2026 PubMed
- "HTG + EPA-E animals showed smaller infarcts (P < 0.05 vs both groups), and MI-related mortality was 29% in EPA-E-treated animals (reaching levels comparable to those of the CD group), whereas it was 56% in HTG animals (P = 0.07)." · Alcover S et al, 2026 PubMed
- "Furan fatty acids (FuFAs) are lipophilic antioxidants that occur in small amounts (≤1% of the total fatty acids) in plants and animals." · Rüttler F et al, 2026 PubMed
- "As a result, 1.2 mg of 11D3-EE with a purity of 95% (recovery: ∼2.5%), 11.3 mg 11D3-EE with a purity of 90% (recovery: ∼23.6%), and 1.2 mg of the trace compound 9D3-EE (95% purity; recovery not determinable) were isolated from the sample initially enriched by hydrogenation and urea complexation." · Rüttler F et al, 2026 PubMed
Research and Studies
12 PubMed-indexed papers reference Icosapent Ethyl (Vascepa). Top 12 shown.
Legal Status
Icosapent Ethyl (Vascepa) is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-09.
Frequently Asked Questions
Is Icosapent Ethyl (Vascepa) FDA-approved?
Icosapent Ethyl (Vascepa) is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
What dosing is reported for Icosapent Ethyl (Vascepa)?
This page aggregates 1 dosing-protocol mention(s) from named-expert transcripts, each linked to a verbatim source timestamp. See the Dosing Protocols table above. Mentions are anecdotal, not medical advice.
How much research has been published on Icosapent Ethyl (Vascepa)?
12 PubMed-indexed paper(s) reference Icosapent Ethyl (Vascepa) in our current research feed. See the Research and Studies section above for citations.